PlainPharmaWatch

CMS Open Payments · Tool

Antares Pharma, Inc. vs Roche Sequencing Solutions, Inc.

Side-by-side comparison of CMS Open Payments data for Program Year 2024. Select different companies below to start a new comparison.

A larger reported total is not "better" or "worse", it is a neutral fact about disclosure volume; a reported payment documents a financial relationship, not evidence of wrongdoing.

Compare Different Companies

vs

Relationship comparison

Which recorded payment profile is more concentrated?

Roche Sequencing Solutions, Inc. has the more concentrated recorded General Payments recipient profile in Program Year 2024: its recipient-distribution HHI is 5,222, versus 119 for the other company. Its single largest recorded recipient represents 0.7% of that company's General Payments recipient total.

HHI summarizes how payments are distributed across recorded recipients: higher means a less evenly distributed recipient pattern. This is a description of CMS-reported General Payments only, not a finding about conduct, prescribing, quality, or wrongdoing. Read it with the recipient count and underlying records below.

Antares Pharma, Inc.
HHI 119 · top recipient 0.1%
Ranked #1,661 of 1,838 companies by HHI
Roche Sequencing Solutions, Inc.
HHI 5,222 · top recipient 0.7%
Ranked #327 of 1,838 companies by HHI

Payment Overview

Total Payments
$489.5K
% of Industry
0.0%
Transactions
19,224
Avg per Transaction
$25.46
Recipients
19,224
Avg per Recipient
$25.46
Payment Types
5
Top Payment Type
Food and Beverage
Total Payments
$491.0K
% of Industry
0.0%
Transactions
6
Avg per Transaction
$81.8K
Recipients
4
Avg per Recipient
$122.8K
Payment Types
3
Top Payment Type
Royalty or License

Highlighted values indicate the higher figure for each metric.

Total payments compared

Antares Pharma, Inc. vs Roche Sequencing Solutions, Inc. - total reported payments in CMS Open Payments PY2024

Roche Sequencing Solutions,…$491.0KAntares Pharma, Inc.$489.5K

Payment Types Breakdown

Antares Pharma, Inc.

Food and Beverage $365.8K

74.7%

Consulting Fee $61.0K

12.5%

Honoraria $57.0K

11.6%

Travel and Lodging $5.1K

1.0%

Compensation for Services Other Than Consulting $586.64

0.1%

Roche Sequencing Solutions, Inc.

Royalty or License $10.0K

2.0%

Compensation for Services Other Than Consulting $2.6K

0.5%

Consulting Fee $1.7K

0.4%

Top 5 General-Payment Recipients

This list uses CMS detailed General Payments records only; it excludes research and ownership/investment records, so it does not equal the all-category totals above. A reported payment documents a financial relationship, not evidence of wrongdoing; a higher total reflects reporting volume, not conduct. Verify directly at openpaymentsdata.cms.gov.

Antares Pharma, Inc.

  1. 1

    CARRIE BROWNSTEIN

    $41,687.50 · 5 txns

  2. 2

    NEEL PAREKH

    $18,536.07 · 17 txns

  3. 3

    ASHLEY TAPSCOTT

    $15,488.18 · 25 txns

  4. 4

    KEITH REGETS

    $14,541.66 · 15 txns

  5. 5

    FAYSAL YAFI

    $11,788.25 · 6 txns

Roche Sequencing Solutions, Inc.

  1. 1

    BRIGHAM AND WOMENS HOSPITAL

    $10,000.00 · 1 txns

  2. 2

    STEPHEN RENNARD

    $1,722.50 · 1 txns

  3. 3

    RENA XIAN

    $1,659.92 · 1 txns

  4. 4

    PAWEL MROZ

    $900.00 · 1 txns

Summary Comparison

Metric Antares Pharma, Inc. Roche Sequencing Solutions, Inc.
Total Payments $489.5K $491.0K
% of Industry Total 0.0% 0.0%
Transaction Count 19,224 6
Avg per Transaction $25.46 $81.8K
Recipient Count 19,224 4
Avg per Recipient $25.46 $122.8K
Payment Type Count 5 3
Top Payment Type Food and Beverage Royalty or License

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. All companies in the CMS Open Payments company corpus are available in the selector. Browse all companies →

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.